HiFiBiO Therapeutics is an emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases.

Our Vision

Pioneer curative immunotherapies for each and every patient

Our Mission

Unlock the curative powers of the immune system with innovative biotherapeutics to improve patient lives

Our Strategy

Advance a sustainable pipeline of breakthrough immunotherapies through single cell driven Drug Intelligence Science (DIS®)

Our Team

Leadership Team

Liang Schweizer, Ph.D.
Founder, Chairperson and CEO
Francisco Adrian, Ph.D.
Chief Scientific Officer
Edward Garmey, M.D.
Interim Chief Medical Officer
Lynn Bodarky, MBA
SVP, Global Head of Business Development and Operations
John Pallante
Senior Vice President, Global Head of Clinical Operations and Quality Management
Christos Hatzis, Ph.D.
Vice President, Global Head of Translational Medicine
Jinping Gan, Ph.D.
Vice President, Global Head of Research
Edward Rocnik, Ph.D.
Executive Director, Global Head of CMC
Rachel Yao, CPA
Financial Controller
Steven Chen, J.D., Ph.D.
General Counsel
Roshan Kumar, Ph.D.
Senior Director, External Innovation
Yun-Yueh Lu, Ph.D.
Senior Director, Discovery Biology and In Vivo Pharmacology
Qian Zhang, Ph.D.
Senior Director, Global Head of Antibody Discovery and Optimization
Pascaline Mary, Ph.D.
Senior Director, Head of Single Cell Science
Vincent Tse, MBA
Senior Director of Staff and Strategy
Sami Ellouze
Managing Director, France
Stephen Beauparlant, Ph.D.
Director of Global Scientific Operations
Chao Kong
Director of China External Innovation

Michael Croft, PhD

Director of Scientific Affairs, Professor and Head of the Division of Immune Regulation at La Jolla Institute for Immunology                                                      

Leslie Kean, MD, PhD

Director of the Stem Cell Transplantation Program and Physician at Dana-Farber/Boston Children’s Cancer Center and Blood Disorders Center

Aurélien Marabelle, MD, PhD

Senior Medical Oncologist in the Drug Development Department and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy

Wendye Robbins, MD

Member Board of Trustees (Buck Institute for Research on Aging), Member Board of Directors (Rapt Therapeutics), Member Board of Directors (California Life Sciences Association)

Sebastian Amigorena, PhD

Director of the INSERM Immunity and Cancer Lab, and head of the Immunology and Immunotherapy department at Institut Curie.

Andrew Griffiths, PhD

Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris

David Weitz, PhD

Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University

Bradley Bernstein, MD, PhD

Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard

Jérôme Bibette, PhD

Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)

Robert Nicol, PhD

Venture Partner at RA Capital Management

Our Investors

We are funded by leading VC firms focused on transforming patient care including Mirae Asset, B Capital Group, IDG Capital, Kite Pharma, Sequoia Capital, LYFE Capital, etc

Open-Innovation Partnerships

We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand DIS® applications and accelerate pipeline commercialization. All our collaborations are architected for speed and driven by our scientific strategy.